Cargando…

Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006

BACKGROUND: Mucosal melanoma is an aggressive melanoma with poor prognosis. We assessed efficacy of pembrolizumab in patients with advanced mucosal melanoma in KEYNOTE-001 (NCT01295827), −002 (NCT01704287), and −006 (NCT01866319). METHODS: Patients received pembrolizumab 2 mg/kg every 3 weeks (Q3W)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hamid, Omid, Robert, Caroline, Ribas, Antoni, Hodi, F. Stephen, Walpole, Euan, Daud, Adil, Arance, Ana S., Brown, Ewan, Hoeller, Christoph, Mortier, Laurent, Schachter, Jacob, Long, Jianmin, Ebbinghaus, Scot, Ibrahim, Nageatte, Butler, Marcus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Brief Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173747/ https://www.ncbi.nlm.nih.gov/pubmed/30202085 http://dx.doi.org/10.1038/s41416-018-0207-6

Ejemplares similares

Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006
por: Hamid, Omid, et al.
Publicado: (2021)

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
por: Hamid, O, et al.
Publicado: (2019)

Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program
por: Gangadhar, Tara C., et al.
Publicado: (2017)

Health-Related Quality of Life with Pembrolizumab in Patients with Locally Advanced or Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: KEYNOTE-629
por: Bratland, Åse, et al.
Publicado: (2023)

Using Model‐Based “Learn and Confirm” to Reveal the Pharmacokinetics‐Pharmacodynamics Relationship of Pembrolizumab in the KEYNOTE‐001 Trial
por: Elassaiss‐Schaap, J, et al.
Publicado: (2016)

Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic
por: Kang, S. P., et al.
Publicado: (2017)

A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma
por: Dummer, Reinhard, et al.
Publicado: (2015)

Pembrolizumab
por: Khoja, Leila, et al.
Publicado: (2015)

Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042
por: Mansfield, Aaron S., et al.
Publicado: (2021)

KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma
por: Ferrucci, Pier Francesco, et al.
Publicado: (2020)

Keynote 42: Pembrolizumab, PD-L1, and where to draw the line
por: Isaacs, James, et al.
Publicado: (2020)

Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study
por: Garon, Edward B., et al.
Publicado: (2019)

Breakthrough 5-year survival with pembrolizumab in Keynote-001 study: horizon shifting in advanced non-small cell lung cancer with immune check point inhibition
por: de Silva, Madhawa, et al.
Publicado: (2020)

Health-Related Quality of Life of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma Treated with Pembrolizumab in KEYNOTE-629
por: Hughes, Brett G. M., et al.
Publicado: (2021)

Pembrolizumab Plus Chemotherapy for Chinese Patients With Metastatic Squamous NSCLC in KEYNOTE-407
por: Cheng, Ying, et al.
Publicado: (2021)

Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma
por: Robert, Caroline, et al.
Publicado: (2020)

Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629)
por: Grob, Jean-Jacques, et al.
Publicado: (2020)

Keynote 407: the combination of pembrolizumab and chemotherapy cracks the shell of squamous cell lung cancer
por: Viteri, Santiago, et al.
Publicado: (2020)

Patterns of response in patients with advanced melanoma treated with Pembrolizumab (MK-3475) and evaluation of immune-related response criteria (irRC)
por: Hodi, F Stephen, et al.
Publicado: (2014)

A Review About Pembrolizumab in First-Line Treatment of Advanced NSCLC: Focus on KEYNOTE Studies
por: Qu, Jialin, et al.
Publicado: (2020)

Pembrolizumab monotherapy in Japanese patients with advanced ovarian cancer: Subgroup analysis from the KEYNOTE‐100
por: Nishio, Shin, et al.
Publicado: (2020)

Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study
por: Gregory, Gareth P., et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Pembrolizumab in Patients With Advanced Esophageal Cancer Based on the KEYNOTE-181 Study
por: Zhan, Mei, et al.
Publicado: (2022)

Pembrolizumab in Chinese patients with advanced melanoma: 3-year follow-up of the KEYNOTE-151 study
por: Si, Lu, et al.
Publicado: (2022)

Pemetrexed and Platinum Plus Pembrolizumab in Patients With Metastatic Nonsquamous NSCLC by Tumor Burden at Baseline: A Post Hoc Efficacy Analysis of KEYNOTE-189
por: Gadgeel, Shirish, et al.
Publicado: (2022)

Keynotes
Publicado: (2023)

Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules
por: Long, Georgina V., et al.
Publicado: (2021)

Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study
por: Cohen, Roger B., et al.
Publicado: (2018)

Pembrolizumab in Patients With Microsatellite Instability–High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study
por: O'Malley, David M., et al.
Publicado: (2022)

Lenvatinib plus pembrolizumab in Japanese patients with endometrial cancer: Results from Study 309/KEYNOTE‐775
por: Yonemori, Kan, et al.
Publicado: (2022)

First-line pembrolizumab + chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590
por: Kojima, Takashi, et al.
Publicado: (2022)

First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048
por: Takahashi, Shunji, et al.
Publicado: (2022)

KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma
por: Tabernero, Josep, et al.
Publicado: (2021)

Pembrolizumab plus chemotherapy in Japanese patients with triple‐negative breast cancer: Results from KEYNOTE‐355
por: Hattori, Masaya, et al.
Publicado: (2023)

Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170
por: Zinzani, Pier Luigi, et al.
Publicado: (2023)

Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma
por: Armand, Philippe, et al.
Publicado: (2023)

Effect of 0.02% and 0.01% atropine on astigmatism: a two-year clinical trial
por: Wang, Ming, et al.
Publicado: (2022)

Pembrolizumab or pembrolizumab plus chemotherapy versus standard of care chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062
por: Satake, Hironaga, et al.
Publicado: (2022)

Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practices
por: Cowey, C. Lance, et al.
Publicado: (2018)

Keynote Address
por: Zinsou, Lionel
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_9bv1km7p3mdco2l78ua765kpab